A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, Benign Breast Disease

Next Previous
Trial Profile

A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, Benign Breast Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Docosahexaenoic acid (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Pharmacodynamics

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Jan 2015 Planned number of patients changed from 63 to 64 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top